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Astrocytes as homeostatic cells in the central nervous system 
 
Out of four main classes of neuroglial cells of the central nervous system (astroglia, 
oligodendroglia, NG2 glia and microglia) astrocytes are arguably the most diverse. Indeed, 
astroglial cells include a huge variety of phenotypes with very different morphology and 
physiological properties. The largest and most characterised types of astroglia are represented by 
the protoplasmic astrocytes of the grey matter and fibrous astrocytes of the white matter. 
Morphological appearance of these cells as well as their physiology differ substantially between 
various brain regions. Another main group of astroglial cells covers the radial glia, which are 
bipolar cells with a small cell body and main processes, one of which forms endfeet on the 
ventricular wall and the other at the pial surface. Radial glia are the main glial type of the 
embryonic brain and generally absent from the mature brain with the exception of the retina 
(Müller glia) and cerebellum (Bergmann glia). Astrocytes are further classified into the velate 
astrocytes of the cerebellum, the interlaminar and polarised astrocytes of the primate cortex, 
tanycytes (found in the periventricular organs, the hypophysis and the raphe part of the spinal 
cord), pituicytes in the neuro-hypophysis, and perivascular and marginal astrocytes. Astroglia 
also include several types of cells that line the ventricles or the subretinal space, namely 
ependymocytes, choroid plexus cells and retinal pigment epithelial cells (see [1,2] for review and 
references). 
 
All these highly diverse cells are united by their function which lies in maintaining the 
homeostasis of the nervous system [1]. To cater for this, astrocytes perform many different 
functions, which embrace every known house-keeping and homeostatic task in the CNS (for 
detailed reviews see [3–12]). Astroglial cells are fundamental for brain development being, for 
example, chief promoters and supporters of synaptogenesis, synaptic maturation and 
maintenance [13,14].  In the adult brain these are astrocytes which act as stem cells in the 
neurogenic niches [15]. Astrocytes define overall brain architecture by forming glial barriers at the 
pia mater and between the brain parenchyma and vasculature; they divide the grey matter into 
neuro-vascular units and contribute to regulation of local blood flow; they are primary elements 
of brain ion homeostasis, they control extracellular pH, they provide neurones with metabolic 
substrates and release scavengers of reactive oxygen species (for detailed reviews see [3–12]). 
Astrocytes are also critical for numerous systemic homeostatic functions such as central 
chemoception [16–18] and regulation of sleep [19]. In the present essay we shall concentrate on a 
single homeostatic function of astroglia, the function which relates to their ability to maintain 
turnover of two principal neurotransmitters in the brain, glutamate and GABA, this function 
being accomplished by glutamate, GABA and glutamine transporters, and by astroglial specific 
enzyme, the glutamine synthetase (GS).  
 
Astrocytes in glutamatergic neurotransmission: glutamate uptake and release  
 
Fundamentally astrocytes contribute to the homeostasis and regulation of extracellular level of 
three key neurotransmitters in the CNS, represented by glutamate, GABA and adenosine [8,20,21]. 
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Astroglial role is multifaceted; (i) it includes an uptake of these neurotransmitters from the 
extracellular cleft, which defines the time course of neurotransmission and (at least in case of 
glutamate) preventing toxicity; (ii) astrocytes are also capable or releasing neurotransmitters 
through vesicular and non-vesicular pathways and (iii) astrocytes catabolise neurotransmitters 
into intermediates, which are then sent back to neurones to be transformed into active molecules, 
thus maintaining synaptic transmission.   
 
Astroglial uptake of glutamate 
 
Glutamic acid, or glutamate, is an amino acid, which in the CNS, acts as the main excitatory 
neurotransmitter released from presynaptic terminals through vesicular exocytotic mechanism. 
To make this mechanism function properly both extra- and intracellular glutamate dynamic 
should be tightly controlled. Glutamate should be removed from the synaptic cleft and at the 
same time the synaptic cleft should be guarded from extrasynaptic glutamate or glutamate 
spillover from neighbouring synapses. Simultaneously the glutamate inside the presynaptic 
terminal should be rapidly replenished.  It is important to note that neurones are incapable of de 
novo synthesis of glutamate; the latter is synthesized in astrocytes [22](see below). Astrocytes also 
provide a principal pathway for glutamate uptake: about 80% of all glutamate released during 
synaptic transmission, is taken up by astroglial cells with only about 20 per being accumulated 
into postsynaptic neurones; presynaptic neurones do not take up glutamate [20,23].  
 
Glutamate uptake by astroglial cells is mediated through plasmalemmal glutamate transporters of 
the solute carrier 1 (SLC1) family [24] represented by 5 main types of Excitatory Amino Acid 
Transporters 1 - 5 (EAAT1/SLC1A3, EAAT2/SLC1A2, EAAT3/SLC1A1, EAAT4/SLC1A6 and 
EAAT5/SLC1A7), of which astrocytes specifically express EAAT-1 and EAAT-2 transporters; 
these in rodents are known as glutamate/aspartate transporter (GLAST) and glutamate 
transporter-1 (GLT-1). Transport of glutamate by EAATs is powered by transmembrane gradient 
of Na+ ions; translocation of single molecule of glutamate (which is a monovalent anion at 
physiological pH) is linked to an influx of three Na+ ions, one H+ ion and efflux of one K+ ion, 
all these movements going downhill along with respective concentration gradients. The 
glutamate transport cycle, therefore, is associated with net cation influx which defines the 
electrogeneity of glutamate transporters that could be measured as an inward current. Uptake of 
physiologically relevant concentrations of glutamate causes substantial sodium influx, which 
may increase intracellular Na+ concentration by tens of mM [25,26]. 
 
Astroglial release of glutamate 
 
Astrocytes can release glutamate by several different mechanisms: (i) reversal of uptake by 
plasma membrane glutamate transporters [27], (ii) opening of anion channels, be that be volume-
regulated anion channels [28] or Ca2+-activated anion channels [29], (iii) Ca2+-dependent exocytosis 
[30], (iv) glutamate exchange via the cystine-glutamate antiporter [31], (v) release through 
ionotropic purinergic receptors [32] and (vi) functional unpaired connexons, “hemichannels”, on 
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the cell surface [33] [for review see [34]]. These mechanisms can be further classified into the 
release through plasmalemmal molecular entities, channels and transporters, and by exocytosis, 
the latter characterized by the formation of an aqueous channel, the fusion pore, upon the merger 
of vesicular and plasma membranes. All of the mechanisms depend on glutamate concentration 
in various cellular compartments and the extracellular space. Conceptually, its anionic 
concentration gradient between the cytosol and the extracellular space directly dictates the 
release via plasmalemmal channels/transporters. However, due to coupling transport of other 
ions, EAATs have their reversal potential at ~ +50 mV [25,35], which means that under normal 
physiological conditions EAATs could not revert to release glutamate [36]. In respect to 
exocytosis, cytosolic glutamate is sequestered into secretory vesicles via vesicular glutamate 
transports (VGLUTs) before it gets released through the fusion pore.  
 
The cytoplasmic glutamate concentrations in astrocytes are maintained different than those in 
neurons [for review see [20]]. The glutamate concentration in the cytosol of synaptic terminals 
reaches 10-15 mM [37]. This permits VGLUTs (Km ~1-2 mM) to operate at nearly their maximal 
rates to concentrate glutamate into synaptic vesicles. Consequently, intravesicular glutamate 
concentration reaches 60 mM [38], which generates estimated ~1.1 mM glutamate concentration 
in the synaptic cleft at time of release [39]. Owing to the powerful action of mainly astroglial 
EAATs, glutamate gets quickly lowered down, so that the resting glutamate concentration in the 
extracellular space of the CNS is maintained at ~25 nM [40]. Presumably due to the presence of 
GS, the cytosolic glutamate concentration in astrocytes is lower than neuronal at estimated 0.1-5 
mM [37]. This is sufficient to allow for the operation of VGLUTs to concentrate glutamate inside 
astrocytic vesicles, which intravesicular concentration is estimated at about ~ 20 mM [41]. 
Consequently, vesicular glutamate release from astrocytes creates localized extracellular 
glutamate accumulations of 1-100 M [42].  
 
In the CNS, glutamate is synthesized de novo within astrocytes as a by-product of the 
tricarboxylic acid (TCA) cycle [43]. Here, as glucose breaks down to pyruvate in the cytosol, 
pyruvate enters mitochondria and the TCA cycle via pyruvate carboxylase, a 
ligase that catalyzes the carboxylation of pyruvate to form oxaloacetate (Fig. 1). In turn, 
glutamate is produced from α-ketoglutarate, a downstream TCA intermediate, by transamination 
of aspartate via mitochondrial aspartate amino transferase. The synthesized glutamate once in the 
cytosol can then be converted to glutamine by GS, or transported into vesicles via VGLUTs, 
especially isoform 3 (VGLUT3) [44] (Fig 2). The role of GS and cytosolic glutamate 
concentrations for exocytotic glutamate release from astrocytes has been experimentally 
demonstrated [44]. To increase the cytosolic glutamate concentration in astrocytes GS activity was 
blocked with L-methionine sulfoximine, which led to an augmented exocytotic glutamate release 
in response to mechanical stimulation [44], while, importantly, Ca2+ dynamics were unaffected by 
this GS blocker. Of note, the mechanical stimulation almost exclusively (97%, based on the pan- 
VGLUT blocker Rose Bengal) recruits the exocytotic/vesicular release of glutamate [45], but not 
glutamate release through, e.g., Ca2+-activated anion channels [46]. Therefore, the impairment of 
GS activity implicates that the increase of cytosolic glutamate concentration provided more 
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glutamate for VGLUTs to transport across the vesicular membrane into the vesicular lumen, thus 
increasing the amount of glutamate in vesicles available for release. Further modulation of 
cytosolic glutamate concentration and its release could also originate from changes that might 
occur at the level of pyruvate carboxylase. Hence, astrocytes from a Huntington’s disease mouse 
model showed an augmented glutamate release as de novo glutamate synthesis was increased due 
to an upsurge in the expression of pyruvate carboxylase, while the conversion of glutamate to 
glutamine was unchanged, as no changes in the expression level of GS were observed [47]. 
Hypothetically, additional modulation of cytosolic glutamate concentration could sprout from the 
metabolic pathway between pyruvate carboxylase and GS. This could involve various 
mitochondrial enzymes, such as the previously mentioned aspartate amino transferase. Similarly, 
SLCs redistributing reactants/products across the inner mitochondrial membrane could also be 
involved, perhaps mitochondrial glutamate carrier 1 (SLC family 25 member 22) and 
mitochondrial aspartate glutamate carrier (SLC family 25 member 13, also called citrin). 
 
Astroglial glutamine-glutamate and glutamine-GABA shuttle 
 
Maintenance of glutamatergic transmission requires constant replenishment of glutamate, which 
in turn relies on astroglial glutamate uptake, glutamate conversion into glutamine and transport 
of the latter into neuronal presynaptic terminals. This coordinated system of fluxes of glutamate 
and glutamine in generally known as glutamate–glutamine shuttle (Fig. 1). This is an energy 
dependent mechanism which requires hydrolysis of one molecule of ATP for a single conversion 
of glutamate to glutamine. Transport of glutamine from astrocytes and into neurones is mediated 
by amino-acid transporters, which have a specific distribution between neurones and 
astrocytes [48]. Astrocytes are in possession of the system N transporters (represented by Na+/H+ 
dependent sodium coupled neutral amino acid transporters SN1/SNAT3/SLC38A3 and 
SN2/SNAT5/SLC38A5 [49,50] which mediate glutamine efflux. Importantly these transporters can 
be relatively easy switched to the reverse mode after, for example, increase in cytosolic Na+ 
concentration. Neurones express another system for glutamine transport, mediated by the system 
A glutamine transporters [51] (the sodium coupled neutral amino acid transporters 
ATA1/SNAT1/SLC38A1 and ATA2/SNAT2/SLC38A2) which act as influx transporters 
mediating glutamine accumulation into the neuronal compartment [52]. There are some exceptions 
however, for example GABAergic neurones express N-transporter SNAT7 [53]. 
 
In presynaptic terminals glutamine hydrolysed to glutamate; incidentally this conversion 
catalysed by phosphate-activated glutaminase, does not require energy. The newly synthesized 
glutamate is subsequently concentrated in synaptic vesicles bearing VGLUT transporters and 
thus releasable pool of glutamate is maintained. The supply of glutamate by astrocytes is 
coordinated with neuronal activity - increase in external concentration of glutamate increases  
release of glutamine [54], this being mediated through glutamate transporters [55] possibly through 
an increase in intracellular Na+ concentration.   
 




Astroglial glutamine is also critical for inhibitory transmission in the CNS mediated by GABA. 
Presynaptic terminals synthetise GABA from glutamate that arrives through glutamate-glutamine 
shuttle; inhibition of the later rapidly inhibits GABAergic transmission [56]; this mechanism is 
often also referred to as GABA-glutamine shuttle or cycle (Fig. 2). The cytosolic concentration of 
GABA in astroglial cells can be quite high, approaching ~2.5 mM [57]. Of note, astrocytes also 
express GABA transporters GAT-1 and GAT-3, which can be readily reversed upon moderate 




In addition to its importance in neurotransmission, GS also plays a significant role in the 
assimilation of ammonia by the brain. Ammonia, a metabolite mainly produced within the 
gastrointestinal system (through protein degradation and amino acid deamination), is primarily 
regulated by the urea cycle; exclusively found in the liver. Ammonia-rich venous blood from the 
gastrointestinal tract first passes through the liver maintaining the circulating concentration of 
ammonia between 35-50 µM. Ammonia, composed of gas (NH3) and ion (NH4
+) components, 
can easily cross all plasma membranes through diffusion, channels and transporters [59]. In the 
setting of liver disease, blood ammonia levels can increase as high as 1mM leading to toxic 
concentrations in the brain and the onset of hepatic encephalopathy, a neuropsychiatric disorder 
involving cognitive alterations and motor impairments. Hyperammonemia also arises in infants 
with inborn errors of urea cycle enzymes causing seizures and coma. Surviving children have a 
high incidence of mental retardation and cerebral palsy. Toxic levels of ammonia trigger changes 
in both pH and membrane potential and have a profound effect on metabolism [59]. The brain is 
particularly susceptible to increased concentrations of ammonia and heavily relies on GS in 
astrocytes to prevent toxicity and neurological dysfunction. It has been demonstrated that an 
increase in brain ammonia elicits an increase in GS activity [60] however Cooper et al. [61] showed 
that under normal physiological conditions, GS activity in the brain operates at near maximal 
capacity, preventing any further induction. In either case, the observation of elevated 
concentrations of ammonia in liver disease reveals that the capacity of GS to detoxify ammonia 
in the brain is limited and therefore cannot compensate to maintain ammonia at physiological 
levels. Moreover, GS activity in brain has been shown to be inhibited in liver disease [62] since an 
increase in cerebral nitric oxide stimulates peroxynitrite-mediated nitration of tyrosine residues 
of GS resulting in inactivation [63]. In turn, a decrease in capacity to clear ammonia in the brain 
detrimentally leads to sustained elevation in brain ammonia and, thus, persisting neurological 
dysfunction [64].             
 
GS mutations in brain 
 
First described by Häberle et al., [65], homozygous mutations in the GS gene (GLUL), as 
observed in two newborns lead to a reduction in GS activity and, consequently, severe brain 
malformations, seizures, multiorgan failure and early death. Surviving infants develop chronic 
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encephalopathy during the neonatal period. Furthermore, mice with prenatal excisions of the GS 
gene die during early embryonic development [66]. Consequently, in addition to causing 
alterations in glutamate/glutamine homeostasis, deficiency in GS consequently impairs the 
detoxification of ammonia; concentrations of ammonia have been demonstrated to rise between 
100-200 µM [67]. These levels of ammonia are comparable to those found in liver disease 
associated with hepatic encephalopathy [68].   
 
CNS disorders and alterations in glutamine synthetase 
 
As GS is an essential part of a complex astrocyte-neuron signaling process, changes in 
expression and activity of GS will lead to neurological dysfunction. A number of different brain 
pathologies are associated with alterations in GS expression/activity. Patients diagnosed with 
medial lobe temporal lobe epilepsy exhibit markedly reduced GS expression and activity in the  
hippocampus despite astroglial proliferation/reactive astrocytes [69,70].  
However, an upregulation of GS has been demonstrated in the hippocampal dentate gyrus during 
seizure acquisition in the amygdala kindling model of epilepsy [71] with, however, no change in 
GS activity found in frontal cortex of epilepsy patients [72]. Overall, it appears that alterations in 
GS activity/expression are region selective depending on the kind of epilepsy. Similarly, a 
decreased in GS expression was found in the striatum of rats with Parkinsonian tremor [73]. 
Postmortem brain tissue collected from Alzheimer’s patients have revealed a reduction in GS 
activity [74,75].  Furthermore, it has been shown that the amount of GS protein in Alzheimer’s 
brains is inversely correlated with the number of beta-amyloid plaques [76] and that a decrease in 
GS is associated with the presence of amyloid beta deposits, as demonstrated in a mouse model 
of Alzheimer’s disease [77]. Moreover, in the brains of patients with schizophrenia, an increase 
and decrease in GS mRNA has been found in specific regions as well [78].   Furthermore, there 
are several lines of evidence that support retinal GS is implicated in diabetic retinopathy. Down 
regulation of GS has been demonstrated to occur during the early stages of diabetes[79–81] . The 
susceptibility of certain brain structures damage (i.e CA1 area of the hippocampus) to hypoxic 
damage is associated with the disappearance of GS; this observation, however, has not been 
demonstrated in brain regions less susceptible to hypoxia [82]. Brain GS mRNA expression has 
also been found to be decreased in patients with depression [83–85]. In addition, increased 
expression of GS through ischemic postconditioning has been shown to be neuroprotective in 
ischemic rats [86]. Overall, changes in GS expression/activity are associated with 
neurodegenerative diseases and mental disorders (Fig. 3).  
  
GS expression in other brain cells?  
 
In addition to GS being particularly localized in astrocytes, GS expression has been measured in 
other cells of the brain. During pathophysiological conditions, such as in patients with 
Alzheimer’s disease, GS was found to be expressed in neurons; a result that was not replicated in 
post-mortem tissue from control brains. Furthermore, GS has also been demonstrated to be 
expressed in microglia of simian immunodeficiency virus(SIV)-infected macaques [87]. However, 
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the role of GS, as well as the cause or effect of GS expression in other cells of the brain, remains 




 Proper astrocyte function is imperative for glutamatergic/GABA physiology. Alterations in GS, 
an exclusive enzyme found in astrocytes, have been shown to be associated with a number of 
neurological disorders. In addition to GS playing a vital role in glutamate homeostasis, it is also 
bears the brunt of ammonia detoxification in the brain. The precise neurotoxic effects following 
alterations in GS, whether due to glutamate or ammonia neurotoxicity, deserves to be further 
investigated. 
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Figure 1: Astrocytes maintain glutamatergic and GABA-ergic transmissions through 
glutamate-glutamine and GABA-glutamine shuttle.  
After entering the astrocyte, glutamate is converted into glutamine, which is then transported 
back to the presynaptic terminals, where it is converted into glutamate in excitatory and into 
GABA in inhibitory synapses; these neurotransmitters subsequently are accumulated into 
synaptic vesicles.   
 
Figure 2: Regulation of glutamate in exocytotic glutamate release from astrocytes.   
Glucose is broken down to pyruvate in the cytosol. In the mitochondrion (mito) pyruvate entry 
through the tricarboxylic acid cycle via pyruvate carboxylase (PC) leads to production of 
oxaloacetate (OAA) and a downstream intermediate, α-ketoglutarate (α-KG).  In turn, glutamate 
(Glut) is synthesized in astrocytes de novo from α-KG by transamination of aspartate via 
mitochondrial aspartate amino transferase (AAT). The synthesized glutamate once in the cytosol 
can then be converted to glutamine (Gln) by glutamine synthetase (GS), or transported into 
vesicles via vesicular glutamate transporters, especially isoform 3 (VGLUT3).  Drawing is not to 
scale. 
 
Figure 3: Alterations in GS and neuropathologies 
 
 
 
 
 



